Tochigi, Japan

Tomohiro Ide



 

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Koga, JP (2003)
  • Ibaragi, JP (2004)
  • Ibaraki, JP (2009)
  • Tochigi, JP (2011 - 2012)
  • Nogi-machi, JP (2018)

Company Filing History:


Years Active: 2003-2018

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Tomohiro Ide: Innovator in AMPK and Glucokinase Activators

Introduction

Tomohiro Ide is a prominent inventor based in Tochigi, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of activators for AMPK and glucokinase. With a total of 7 patents to his name, Ide's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Ide has developed an AMPK activator screening method. This method utilizes the inhibition of the interaction between prohibitin and AMPK as an index for screening potential activators. Additionally, he has created an AMPK activator that comprises a compound inhibiting this interaction, along with a prohibitin-AMPK complex. Furthermore, Ide has patented a glucokinase activator represented by a specific chemical formula, which includes various substituents that enhance its pharmaceutical applicability.

Career Highlights

Throughout his career, Tomohiro Ide has worked with notable companies such as Kyorin Pharmaceutical Co., Ltd. and Teijin Pharma Limited. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Ide has collaborated with esteemed colleagues, including Koji Murakami and Yasumichi Fukuda. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Tomohiro Ide's innovative work in AMPK and glucokinase activators showcases his dedication to advancing biochemistry. His patents reflect a commitment to developing new therapeutic solutions that could benefit many.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…